Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
117.60
+2.27 (1.97%)
Jun 6, 2025, 9:54 AM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.62B in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
53.22B
Revenue Growth
+11.50%
P/S Ratio
4.34
Revenue / Employee
701.37K
Employees
75,883
Market Cap
230.96B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Novartis AG News
- 4 days ago - Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug - Benzinga
- 4 days ago - Novartis' Pluvicto shown to slow prostate cancer in earlier setting - Reuters
- 4 days ago - Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial - WSJ
- 4 days ago - Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer - GlobeNewsWire
- 8 days ago - Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
- 10 days ago - Novartis announces commencement of tender offer to acquire Regulus Therapeutics - GlobeNewsWire
- 17 days ago - If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition) - Seeking Alpha
- 22 days ago - New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline - GlobeNewsWire